His primary areas of study are Mesenchymal stem cell, Immunology, Immune system, Cancer research and Cell biology. His work deals with themes such as Cell culture, Stromal cell, Clinical trial and Bone marrow, which intersect with Mesenchymal stem cell. Jacques Galipeau combines subjects such as Progenitor cell and Transplantation with his study of Immunology.
Jacques Galipeau combines subjects such as Interferon and Cell therapy with his study of Immune system. Jacques Galipeau interconnects Ex vivo, In vivo, Paracrine signalling, Stem cell and Innate immune system in the investigation of issues within Cancer research. His Cell biology research incorporates elements of Molecular biology, Antigen processing, Clinical uses of mesenchymal stem cells and Fibroblast growth factor.
Jacques Galipeau mainly focuses on Mesenchymal stem cell, Immunology, Cancer research, Immune system and Stromal cell. His studies in Mesenchymal stem cell integrate themes in fields like Stem cell, Cell therapy and Bone marrow. Jacques Galipeau usually deals with Immunology and limits it to topics linked to Cytotoxic T cell and Antigen.
His Cancer research research includes elements of Adoptive cell transfer, Genetic enhancement, Paracrine signalling and In vivo. As a part of the same scientific family, Jacques Galipeau mostly works in the field of Genetic enhancement, focusing on Molecular biology and, on occasion, Cell culture. His work carried out in the field of Immune system brings together such families of science as Inflammation, Receptor and Indoleamine 2,3-dioxygenase.
Jacques Galipeau focuses on Mesenchymal stem cell, Cancer research, Bone marrow, Cell biology and Stem cell. He has researched Mesenchymal stem cell in several fields, including Stromal cell, Paracrine signalling, Downregulation and upregulation, Immune system and Graft-versus-host disease. His Immune system research integrates issues from Matrix and Cytokine.
His Cancer research study integrates concerns from other disciplines, such as Phenotype, Interferon gamma, B cell, Adoptive cell transfer and Peripheral blood mononuclear cell. His Bone marrow research is classified as research in Immunology. His work on T cell as part of his general Immunology study is frequently connected to Statement, thereby bridging the divide between different branches of science.
The scientist’s investigation covers issues in Mesenchymal stem cell, Cancer research, Clinical trial, Stem cell and Stromal cell. His Mesenchymal stem cell study incorporates themes from Immune system, Downregulation and upregulation and Homing, Bone marrow. His Immune system study frequently involves adjacent topics like Cytokine.
His Cancer research research is multidisciplinary, relying on both Interferon, Cancer, Internal medicine and Mechanism of action. His biological study spans a wide range of topics, including Cell therapy, In vivo and Intensive care medicine. His Stromal cell study combines topics from a wide range of disciplines, such as Cell and Paracrine signalling.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Mesenchymal Stromal Cells: Clinical Challenges and Therapeutic Opportunities
Jacques Galipeau;Luc Sensébé.
Cell Stem Cell (2018)
Marrow stromal cells for cellular cardiomyoplasty: Feasibility and potential clinical advantages
Jih Shiuan Wang;Dominique Shum-Tim;Jacques Galipeau;Edgar G. Chedrawy.
The Journal of Thoracic and Cardiovascular Surgery (2000)
Human MSC suppression correlates with cytokine induction of indoleamine 2,3-dioxygenase and bystander M2 macrophage differentiation.
Moïra François;Raphaëlle Romieu-Mourez;Raphaëlle Romieu-Mourez;Mengyang Li;Jacques Galipeau;Jacques Galipeau.
Molecular Therapy (2012)
Allogeneic marrow stromal cells are immune rejected by MHC class I– and class II–mismatched recipient mice
Nicoletta Eliopoulos;John Stagg;Laurence Lejeune;Sandra Pommey.
The mesenchymal stromal cells dilemma—does a negative phase III trial of random donor mesenchymal stromal cells in steroid-resistant graft-versus-host disease represent a death knell or a bump in the road?
Airway delivery of mesenchymal stem cells prevents arrested alveolar growth in neonatal lung injury in rats.
Timothy van Haaften;Roisin Byrne;Sebastien Bonnet;Gael Y. Rochefort.
American Journal of Respiratory and Critical Care Medicine (2009)
Mesenchymal Stromal Cells Ameliorate Experimental Autoimmune Encephalomyelitis by Inhibiting CD4 Th17 T Cells in a CC Chemokine Ligand 2-Dependent Manner
Moutih Rafei;Philippe M. Campeau;Adriana Aguilar-Mahecha;Marguerite Buchanan.
Journal of Immunology (2009)
Interferon-γ-stimulated marrow stromal cells: a new type of nonhematopoietic antigen-presenting cell
John Stagg;Sandra Pommey;Sandra Pommey;Nicoletta Eliopoulos;Nicoletta Eliopoulos;Jacques Galipeau;Jacques Galipeau.
Immunological characterization of multipotent mesenchymal stromal cells--The International Society for Cellular Therapy (ISCT) working proposal.
Mauro Krampera;Jacques Galipeau;Yufang Shi;Karin Tarte.
Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation.
Borhane Annabi;Ying‐Ta Lee;Sandra Turcotte;Emmanuelle Naud.
Stem Cells (2003)
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: